Our findings also highlight divergence in the molecular mechanisms underlying resistance to STING agonists in genomically distinct melanomas suggesting consideration of more personalized approaches for optimal anti-tumor efficacy in prospective STING agonist-based clinical trials. This evidence concerns the gene STING1 and neoplasm.